Modified influenza virus for monitoring and improving vaccine efficiency (SJ-04-0033)
- *Abstract
-
The inventors found that the conversion of serine at position 223 to asparagine (N223) in the HA protein of the H5N1 influenza virus increased the sensitivity of a hemagglutinin inhibition (HI) assay in which this protein was used. This N223 change alters receptor specificity and/or antibody-antigen binding. The inclusion of the N223 residue in the HA proteins of diagnostic reference viruses may facilitate the evaluation of vaccine efficacy in humans.
Key words: Influenza, H5N1, hemagglutination inhibition assay
Granted patents or published applications: US Patent No. 7,871,626
Related scientific references: Hoffmann E, et al., "Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza vaccines" Proc Natl Acad Sci 102(36):12915-12920 (2005).
- Country/Region
- USA
